Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study

Hepatology

Volumn 66, Issue 3, 2017, Pages 784-793

  Lai, Tai Shuan ^a,b   Lee, Mei Hsuan ^c   Yang, Hwai I ^d   You, San Lin ^e,f   Lu, Sheng Nan ^g   Wang, Li Yu ^h   Yuan, Yong ⁱ   L'Italien, Gilbert ^i,j   Chien, Kuo Liong ^b   Chen, Chien Jen ^b,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^h MACKAY MEDICAL COLLEGE   (Taiwan)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; VIRUS RNA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; TAIWAN; VIRUS LOAD; AGE DISTRIBUTION; COMORBIDITY; DISEASE COURSE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO; SURVIVAL ANALYSIS; TIME FACTOR;

ADULT; AGE DISTRIBUTION; AGED; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TAIWAN; TIME FACTORS; VIRAL LOAD;

EID: 85025079352     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29192     Document Type: Article

References (33)

1. Foley RN, Collins AJ. The USRDS: what you need to know about what it can and can't tell us about ESRD. Clin J Am Soc Nephrol 2013;8:845-851.
2. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009;5:677-689.
3. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-470.
4. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl.):S45-S57.
5. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006;44:15-22.
6. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009;4:207-220.
7. Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005;45:684-689.
8. Iwasa Y, Otsubo S, Sugi O, Sato K, Asamiya Y, Eguchi A, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol 2008;12:53-57.
9. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006;17:1168-1174.
10. Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol 2007;2:715-721.
11. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res 2008;38:775-783.
12. Moe SM, Pampalone AJ, Ofner S, Rosenman M, Teal E, Hui SL. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis 2008;51:885-892.
13. Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis 2010;56:23-31.
14. Asrani SK, Buchanan P, Pinsky B, Rey LR, Schnitzler M, Kanwal F. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol 2010;8:79-84.
15. Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis 2011;57:396-402.
16. US Renal Data System. 2013 USRDS Annual Data Report: International Comparisons. http://www.usrds.org/2013/pdf/v2_ch12_13.pdf.
17. Hisada M, Chatterjee N, Kalaylioglu Z, Battjes RJ, Goedert JJ. Hepatitis C virus load and survival among injection drug users in the United States. Hepatology 2005;42:1446-1452.
18. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol 2005;43:590-598.
19. Sun CA, Chen HC, Lu CF, You SL, Mau YC, Ho MS, et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999;59:290-296.
20. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010;28:4587-4593.
21. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
22. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005;104:157-163.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
24. Crook ED, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 2005;28:2187-2191.
25. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167:1271-1276.
26. Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int 2012;6:369-378.
27. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012;26:1917-1926.
28. Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013;208:1240-1249.
29. Gomez-Gutierrez C, Chavez-Tapia NC, Ponciano-Rodriguez G, Uribe M, Mendez-Sanchez N. Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. Ann Hepatol 2015;14:807-814.
30. Schneeberger PM, Keur I, van der Vliet W, van Hoek K, Boswijk H, van Loon AM, et al. Hepatitis C virus infections in dialysis centers in the Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998;36:1711-1715.
31. Su Y, Yan R, Duan Z, Norris JL, Wang L, Jiang Y, et al. Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: a multicenter study in Beijing, China. J Med Virol 2013;85:425-432.
32. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
33. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.